The future of regulatory compliance and GMP in pharma, biotech, and medical device industries is being transformed by AI. AI-powered regulatory intelligence, predictive analytics, and automation are significantly improving compliance efficiency, but regulatory agencies are still defining the scope of AI governance in GMP.
By the end of this session, attendees will:
Areas Covered in the Session:-
Background:-
Artificial Intelligence (AI) is revolutionizing regulatory compliance, quality assurance, and GMP practices across the pharmaceutical, biotech, and medical device industries. As regulatory agencies such as the FDA, EMA, MHRA, and PMDA evolve their frameworks, AI is playing an increasingly vital role in automating compliance, ensuring data integrity, enhancing quality systems, and optimizing manufacturing processes.
This webinar, led by Dr. David Lim, Ph.D., will provide an in-depth exploration of how AI is reshaping regulatory affairs, GMP compliance, and quality management systems (QMS), helping companies navigate challenges in AI validation, regulatory expectations, and implementation strategies.
Why Should You Attend?
Regulatory agencies are tightening compliance requirements while companies struggle with manual, paper-based, and outdated quality management systems. AI is a game-changer, offering the potential to:
However, the regulatory landscape for AI in GMP compliance is still evolving, and improper AI implementation can lead to compliance risks, FDA warnings, and regulatory rejections.
This webinar will help you understand how to leverage AI responsibly and compliantly while avoiding pitfalls that could result in compliance failures and financial losses.
Who Will Benefit?
* Download the Order Form
* For 6+ attendees call us at + 1 (844) 449-0244 or mail us at cs@currentwebinar.com
Integrating AI and ChatGPT into Project Management for Better FDA Compliance
How to Prepare for a Regulatory Inspection: FDA, EMA, and Notified Body Audits
Navigating FDA Inspections Successfully - Most Common Observations and Prevention Strategies
Excel Spreadsheet Validation for Part 11 to Eliminate 483s
Excel Spreadsheets; Ensuring Data Integrity and 21 CFR Part 11 Compliance 2025
Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Consulting Firm, Regulatory Doctor (www.RegulatoryDoctor.us). Dr. Lim is a leading industry speaker and has presented and addressed FDA regulatory and compliance matters in various forums and meetings.
Dr. Lim has helped both pharma and medical device industry for regulatory, clinical and compliance matters. Dr. Lim has also advised many firms including, but not limited to risk management firms, venture capital firms, asset management firms, and fund managers to make right investment decisions in view of FDA regulatory and compliance matters.